Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Gilead Sciences, Inc. — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.32, while Gilead Sciences, Inc. trades at $136.91 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| EWU | GILD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $155.80 |
52-Week Low | $40.90 | $110.56 |
Market Cap | — | $168.35B |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.38, down 0.23% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, facing mixed sentiment from oil price volatility and geopolitical tensions in the Middle East. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake, reflecting divergent views on UK market exposure.
The outlook for EWU hinges on UK economic resilience amid political transitions and energy market fluctuations. Opportunities include diversification into developed market leaders, but risks involve sustained oil price pressures and regional instability. Analyst consensus remains neutral, with the ETF serving as a tactical play on British equities rather than a growth-centric investment.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
